News

The agreement expands upon the strategic manufacturing alliance entered in December 2012 concerning the North Carolina facility. As part of the new deal, Eisai will transfer to Biogen

Epiduo Forte Gel is the first combination of retinoid, adapalene and benzoyl peroxide, developed for the moderate to severe acne population. Acne is the most common skin condition

The open-label, single-arm, multicenter trial showed blinatumomab monotherapy induced a complete remission or complete remission with partial hematological recovery within two cycles of treatment in a clinically meaningful

Evotaz (atazanavir 300mg and cobicistat 150mg) tablets are approved for use in combination with other antiretroviral agents to treat HIV-1 infected adults without known mutations associated with resistance

Currently, benralizumab is in Phase III development for the treatment of severe uncontrolled asthma and COPD. Benralizumab targets the IL-5 receptor and reduces eosinophils, which play a major

The contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), as part of the National Institutes of Health (NIH), an agency of the United

The transaction provides Panther Biotechnology with a proprietary, multinational patent protected, ligand-drug conjugate technology platform as well as a pipeline of drug product candidates that address unmet medical

"The issuance of this 9th U.S. patent in our global RPE portfolio represents yet another example of the leadership position we have established as pioneers in Regenerative Ophthalmology,"

"Strong partnerships and coordination across our global study base to identify eligible patients and collect tumor samples have led to successful enrollment for the largest clinical trial ever